This Stock Could Make Headlines
This stock offers a lot of potential in this bear market.
Get more details right here.
Jay M. Short, insider at BioAtla

Jay M. Short Insider Information

CEO of BioAtla
Dr. Short is a cofounder of BioAtla© and co-inventor of the BioAtla's patented Conditionally Active Biologics (CAB) platform. He also cofounded Diversa Corporation (now BASF), a pioneering developer of enzymes, antibodies and biologically active compounds, and served in multiple roles including CEO, President and CTO from 1994 to 2005. He led Diversa's public offering, raising over $200 million, which was the largest biotechnology IPO at that time. Prior to Diversa, Dr. Short served as President of Stratacyte, an antibody engineering company and subsidiary of Stratagene (now Agilent), which together with Scripps Clinic was the first to clone and screen human antibody libraries in E. coli. During this time he also served as VP of R&D and Operations for Stratagene Cloning Systems. Dr. Short received his B.A in Chemistry with Honors from Taylor University. At Case Western Reserve University he received his Ph.D. in Biochemistry with additional studies in Macromolecular Science. He is the author of more than 100 publications and is the inventor of over 500 issued patents.

In 2006, Dr. Short was shortlisted by the editors of Nature Biotechnology as one of the people who made the most significant contribution to biotech in the past decade. He is the recipient of numerous other awards, including Ernst & Young's Entrepreneur of the Year Award, the American Chemical Society's Henry F. Whalen, Jr. Award for Business Development, Adaptive Business Leaders' Innovations in HealthCare Gold Award, two of Connect's first place Most Innovative Product Awards, and in 2010 received an international Best-of-the-Best award from the Young Presidents Organization (YPO). Dr. Short's board experience includes 15 years as a director of Invitrogen (now Thermo Fisher), Senomyx, and Taxon Biosciences (now Dupont). He is a member of YPO/WPO and a founder of Capia IP and the E.O. Wilson Biodiversity Foundation. Dr. Short serves as an advisor to educational, commercial, scientific and charitable organizations.

What is Jay M. Short's net worth?

The estimated net worth of Jay M. Short is at least $3.97 million as of June 21st, 2022. Dr. Short owns 1,335,674 shares of BioAtla stock worth more than $3,966,952 as of June 28th. This net worth estimate does not reflect any other assets that Dr. Short may own. Additionally, Dr. Short receives an annual salary of $1,020,000.00 as CEO at BioAtla. Learn More about Jay M. Short's net worth.

How old is Jay M. Short?

Dr. Short is currently 64 years old. There are 5 older executives and no younger executives at BioAtla. Learn More on Jay M. Short's age.

What is Jay M. Short's salary?

As the CEO of BioAtla, Inc., Dr. Short earned a total compensation package of $11,665,083.00 in 2020. Dr. Short earned a salary of $635,983.00, stock awards of $10,246,083.00, options awards of $361,423.00, non-equity compensation of $421,594.00, and no other miscellaneous compensation. Learn More on Jay M. Short's salary.

How do I contact Jay M. Short?

The corporate mailing address for Dr. Short and other BioAtla executives is , , . BioAtla can also be reached via phone at 858-558-0708 and via email at [email protected] Learn More on Jay M. Short's contact information.

Has Jay M. Short been buying or selling shares of BioAtla?

During the past quarter, Jay M. Short has bought $81,138.78 in shares of BioAtla stock. As far as recent transactions, 0 shares of the business's stock in a transaction that occurred on Tuesday, June 28th. Learn More on Jay M. Short's trading history.

Who are BioAtla's active insiders?

BioAtla's insider roster includes Guy Levy (Director), Jay Short (CEO), Eric Sievers (Insider), Scott Smith (President), Lawrence Steinman (Director), Christian Vasquez (Insider), and Richard Waldron (CFO). Learn More on BioAtla's active insiders.

Are insiders buying or selling shares of BioAtla?

During the last year, BioAtla insiders bought shares 3 times. They purchased a total of 53,234 shares worth more than $153,860.86. During the last year, insiders at the sold shares 26 times. They sold a total of 693,633 shares worth more than $26,002,468.31. The most recent insider tranaction occured on June, 21st when CEO Jay M Phd Short bought 29,082 shares worth more than $81,138.78. Insiders at BioAtla own 35.5 % of the company. Learn More about insider trades at BioAtla.

Information on this page was last updated on 6/21/2022.

Jay M. Short Insider Trading History at BioAtla

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/21/2022Buy29,082$2.79$81,138.781,335,674View SEC Filing Icon  
12/1/2021Sell24,321$23.03$560,112.63View SEC Filing Icon  
11/29/2021Sell15,435$23.89$368,742.15View SEC Filing Icon  
11/24/2021Sell17,022$24.87$423,337.14View SEC Filing Icon  
11/22/2021Sell15,675$26.23$411,155.25View SEC Filing Icon  
8/24/2021Sell4,533$41.60$188,572.801,441,508View SEC Filing Icon  
6/21/2021Sell55,000$39.13$2,152,150.001,441,508View SEC Filing Icon  
6/17/2021Sell19,269$39.22$755,730.181,441,508View SEC Filing Icon  
See Full Table

Jay M. Short Buying and Selling Activity at BioAtla

This chart shows Jay M Phd Short's buying and selling at BioAtla by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioAtla Company Overview

BioAtla logo
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Read More

Today's Range

Now: $2.97
Low: $2.88
High: $3.08

50 Day Range

MA: $2.82
Low: $2.13
High: $4.08

2 Week Range

Now: $2.97
Low: $2.01
High: $47.86


599,018 shs

Average Volume

669,830 shs

Market Capitalization

$111.12 million

P/E Ratio


Dividend Yield



New Investing App Saves Investors an Average of $97,347
Most people are terrible at buying and selling stocks at the right time, but the TradeSmith app takes the emotion out of investing.

Our back test shows, the average investor would've made $97,347 more just by using the TradeSmith app analyzer software.

Check out this FREE video.